PAF1/HIF1α Axis Promotes Pancreatic Cancer Aggressiveness by Regulating Glycolytic Metabolism Background Pancreatic cancer (PC) is a highly aggressive malignant tumor, with pancreatic ductal adenocarcinoma (PDAC) being the most common type. Despite significant advancements in cancer treatment in recent years, the 5-year survival rate for pancreatic...

RhoF Promotes Snail1 Lactylation by Enhancing PKM2-Mediated Glycolysis to Induce Pancreatic Cancer Cell Endothelial–Mesenchymal Transition Academic Background Pancreatic cancer (PC) is a highly malignant tumor characterized by late diagnosis, strong invasiveness, and resistance to systemic therapy, leading to poor patient prognosis. Despite recent ...

Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results from an International Multicenter Study Academic Background Intraductal Papillary Mucinous Neoplasm (IPMN) is the most common type of pancreatic cyst, and its incidence and prevalence have been increasing due to the widespread use ...

Genomic Characteristics of a Rare Pancreatic Cancer Undifferentiated Sarcomatoid Carcinoma Subtype Academic Background Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest cancers, characterized by early invasion and metastasis. Undifferentiated Sarcomatoid Carcinoma (USC) is a particularly aggressive but rare subtype of PDAC, accounting...

Mechanisms of Resistance to Carcinogenic KRAS Inhibition in Pancreatic Cancer Background Pancreatic Ductal Adenocarcinoma (PDAC) is a highly lethal disease. Most patients are diagnosed at an advanced stage and typically die within 12 months, primarily due to limited treatment options and poor response to standard chemotherapy. KRAS is the most crit...